Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy
- PMID: 28687071
- PMCID: PMC5501116
- DOI: 10.1186/s12879-017-2571-x
Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy
Abstract
Background: Leishmaniasis is a protozoan disease caused by parasites of the genus Leishmania, transmitted to humans by sandflies. The diagnosis of leishmaniasis is often challenging as it mimics many other infectious or malignant diseases. The disease can present in three ways: cutaneous, mucocutaneous, or visceral leishmaniasis, which rarely occur together or consecutively.
Case presentation: The patient was a 52 years old immunosuppressed Belgian woman with a long history of severe rheumatoid arthritis. She underwent bone marrow biopsy to explore thrombocytopenia. Diagnosis of visceral leishmaniasis was made by identification of Leishman Donovan (LD) bodies in macrophages. Treatment with liposomal amphotericin B was successful. She later developed cutaneous leishmaniasis treated with amphotericin B lipid complex. She next presented with relapsing cutaneous lesions followed by rapidly progressing lymphadenopathies. Biopsy confirmed the diagnosis of leishmaniasis. Treatments by miltefosine, amphotericin B, N-methyl-glucamine antimoniate were subsequently initiated. She later presented a recurrent bone marrow involvement treated with intramuscular paromomycin and miltefosine. She died two years later from leukemia. At the time of death, she presented with a mucosal destruction of the nose. A Leishmania-specific PCR (Polymerase Chain Reaction) identified L. infantum as etiological agent.
Conclusions: Clinicians should be aware of the potential concomitant or sequential involvement of multiple anatomic localizations of Leishmania in immunosuppressed patients.
Keywords: Cutaneous leishmaniasis; Immunosuppression; Microbiology; Mucosal leishmaniasis; Parasitology; Visceral leishmaniasis.
Conflict of interest statement
Ethics approval and consent to participate
Not Applicable.
Consent for publication
Consent to publish was obtained from a next-of-kin after the patient’s death.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures


Similar articles
-
Leishmaniasis.Lancet. 1999 Oct 2;354(9185):1191-9. doi: 10.1016/S0140-6736(98)10178-2. Lancet. 1999. PMID: 10513726 Review.
-
Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review.BMC Infect Dis. 2015 Nov 23;15:543. doi: 10.1186/s12879-015-1260-x. BMC Infect Dis. 2015. PMID: 26592919 Free PMC article. Review.
-
Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.Am J Trop Med Hyg. 2009 Mar;80(3):336-8. Am J Trop Med Hyg. 2009. PMID: 19270277
-
Leishmaniasis in immunosuppressed individuals.Clin Microbiol Infect. 2014 Apr;20(4):286-99. doi: 10.1111/1469-0691.12556. Epub 2014 Feb 20. Clin Microbiol Infect. 2014. PMID: 24450618 Review.
-
A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure.BMC Infect Dis. 2017 Jan 17;17(1):81. doi: 10.1186/s12879-017-2192-4. BMC Infect Dis. 2017. PMID: 28095796 Free PMC article.
Cited by
-
Unusual clinical presentation of cutaneous leishmaniasis in a patient with corticosteroid-induced immunosuppression.Clin Case Rep. 2020 Nov 24;9(1):133-136. doi: 10.1002/ccr3.3482. eCollection 2021 Jan. Clin Case Rep. 2020. PMID: 33489148 Free PMC article.
-
Recurrent mucosal leishmaniasis of the epiglottis in an immunosuppressed patient.IDCases. 2023 Jul 25;33:e01860. doi: 10.1016/j.idcr.2023.e01860. eCollection 2023. IDCases. 2023. PMID: 37554428 Free PMC article.
-
Visceral Dissemination of Mucocutaneous Leishmaniasis in a Kidney Transplant Recipient.Pathogens. 2020 Dec 30;10(1):18. doi: 10.3390/pathogens10010018. Pathogens. 2020. PMID: 33396614 Free PMC article.
-
Evaluation of the In Vitro Antiparasitic Effect of the Essential Oil of Cymbopogon winterianus and Its Chemical Composition Analysis.Molecules. 2022 Apr 25;27(9):2753. doi: 10.3390/molecules27092753. Molecules. 2022. PMID: 35566105 Free PMC article.
-
Secondary Prophylaxis with Liposomal Amphotericin B in a Patient with Mucosal Leishmaniasis Undergoing Immunobiological Therapy for Active Ankylosing Spondylitis.Am J Trop Med Hyg. 2019 Aug;101(2):402-403. doi: 10.4269/ajtmh.19-0066. Am J Trop Med Hyg. 2019. PMID: 31219006 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials